首页> 美国卫生研究院文献>Internal Medicine >Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions
【2h】

Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions

机译:达卡他韦和Asunaprevir联合治疗引起的肝炎和胆囊炎伴有超敏反应引起的凝血障碍

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A 70-year-old woman with chronic hepatitis C was admitted to our hospital due to liver injury, cholecystitis, and disseminated intravascular coagulation with a fever and skin rash. She had been on a combination regimen of daclatasvir and asunaprevir for 2 weeks of a 24-week regimen. Because of the symptoms, laboratory findings, results of a drug-induced lymphocyte stimulation test, and pathological findings of liver biopsy, we diagnosed her with drug-induced liver injury. Although daclatasvir and asunaprevir combination therapy is generally well-tolerated, some serious adverse effects have been reported. Our findings indicate that immunoallergic mechanisms were associated with daclatasvir and asunaprevir-induced liver injury.
机译:一名70岁的慢性丙型肝炎妇女因肝损伤,胆囊炎,发散性血管内凝血,发烧和皮疹而入院。在24周的疗程中,她接受了达卡他韦和Asunaprevir的联合治疗2周。由于症状,实验室检查结果,药物诱导的淋巴细胞刺激试验的结果以及肝活检的病理结果,我们诊断出她患有药物诱导的肝损伤。尽管达卡他韦和阿司那普韦联合治疗通常耐受性良好,但已报道了一些严重的不良反应。我们的发现表明,免疫过敏机制与达卡他韦和阿苏那普韦诱导的肝损伤有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号